title: Anatomic changes in the abdominal cavity during intraperitoneal chemotherapy: prospective study using scintigraphic peritoneography.
abstract: Twenty-one patients undergoing either adjuvant or palliative intraperitoneal (ip) chemotherapy had repeated scintigraphic peritoneographies. Significant scintigraphic ip changes were recorded in 11 patients (52%). In patients without residual disease at the time of ip chemotherapy, the rate of ip mal-distribution reached 70%. These alterations did not correlate with clinical complications. Our study suggested that, independently of clinical assessment, scintigraphic peritoneography is a useful test for identifying patients who are no longer suitable for ip treatment, due to inadequate locoregional distribution.
authors.affiliation: Départment of Medical Oncology, Centre Claudius-Regaud, Toulouse, France.
authors.forename: M
authors.initials: M
authors.lastname: de Forni
authors.forename: A
authors.initials: A
authors.lastname: Boneu
authors.forename: P
authors.initials: P
authors.lastname: Otal
authors.forename: P
authors.initials: P
authors.lastname: Martel
authors.forename: R
authors.initials: R
authors.lastname: Shubinski
authors.forename: R
authors.initials: R
authors.lastname: Bugat
authors.forename: H
authors.initials: H
authors.lastname: Lucot
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010529:Peritoneal Cavity / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D013668:Technetium Tc 99m Aggregated Albumin / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D013668:Technetium Tc 99m Aggregated Albumin